Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC

Summary

The purpose of this study is to investigate the effect of the adminstration of celecoxib, a cox2-inhibitor in patients with stage II-III non small cell lung cancer receiving radical radiotherapy. The hypothesis is that celecoxib will increase the remission rate of radiotherapy.

Timeline

Start

2003-05

Primary completion

—

Completion

2008-01

Drugs

Indications